Addiction Neuroscience Explained: Dopamine, Wanting, and Withdrawal

Addiction Rewires the Brain — Literally

Prolonged drug use produces measurable structural and functional changes in the human brain that persist long after drug use stops. Neuroimaging studies of cocaine-dependent individuals show reduced gray matter volume in prefrontal cortex, reduced D2 receptor density in the striatum, and blunted dopaminergic responses to natural rewards. These are not personality failures — they are adaptations of a brain that has been repeatedly flooded with a chemical signal of overwhelming intensity. Understanding these changes is the foundation of modern addiction medicine.

The VTA-to-Nucleus Accumbens Dopamine Circuit

The mesolimbic dopamine pathway runs from the ventral tegmental area (VTA), a cluster of dopamine-producing neurons in the midbrain, to the nucleus accumbens (NAc) in the ventral striatum. This circuit, sometimes called the "reward circuit," is activated by naturally rewarding stimuli — food, sex, social interaction — and is the primary target through which virtually all addictive substances exert their reinforcing effects, despite using different molecular mechanisms.

• Cocaine and amphetamines: block dopamine reuptake transporter (DAT) or reverse it, flooding the synapse with dopamine at the NAc. Cocaine produces dopamine increases 3–5 times above baseline within seconds.
• Opioids: bind mu-opioid receptors on GABAergic interneurons in the VTA, disinhibiting dopamine neurons and increasing their firing rate — an indirect dopamine increase.
• Alcohol: multiple mechanisms including GABA-A potentiation, NMDA antagonism, and endogenous opioid release, collectively increasing NAc dopamine.
• Nicotine: binds nicotinic acetylcholine receptors on VTA dopamine neurons, directly stimulating their firing.

Wanting vs. Liking — Berridge's Distinction

Kent Berridge at the University of Michigan has produced some of the most influential addiction neuroscience of the past three decades through his incentive salience theory. The core insight: the brain systems for "wanting" (motivational drive to obtain a reward) and "liking" (hedonic pleasure from the reward) are neurochemically distinct.

"Liking" — the hedonic impact of pleasure — is mediated by opioid and endocannabinoid systems in small "hedonic hotspots" within the NAc shell and elsewhere. "Wanting" — the motivational salience driving approach and consumption — is mediated by mesolimbic dopamine. In addiction, dopamine-driven "wanting" escalates while opioid-driven "liking" does not. This explains the clinical paradox: addicted individuals compulsively seek and use substances they describe as providing progressively less pleasure. The system that drives seeking has become hypersensitized; the system that generates pleasure has not. The addict wants intensely. Likes less and less.

Tolerance and the Opposing Process

Repeated drug exposure triggers homeostatic adaptations that reduce the drug's effect and shift baseline functioning in the opposite direction. The opponent process theory (Solomon and Corbit, 1974) describes the "b process" — the brain's counterreaction to any intense stimulus. In addiction, this b process — manifesting as dysphoria, anxiety, and physical withdrawal — grows stronger and persists longer with repeated use. Initial drug use: A process (euphoria) dominant, b process (mild withdrawal) weak. Chronic use: A process (minimal high) diminished by tolerance, b process (powerful withdrawal) dominant. Continued use to avoid the b process is negative reinforcement — using to stop feeling bad rather than to feel good.

Withdrawal Neurobiology

Corticotropin-releasing factor (CRF) and norepinephrine are the key neurochemical drivers of opioid withdrawal. The locus coeruleus — the brain's main noradrenergic nucleus — becomes hyperactive during opioid withdrawal, producing the characteristic anxiety, tachycardia, piloerection, and GI symptoms. Clonidine, an alpha-2 agonist that suppresses noradrenergic firing, provides significant symptom relief during opioid withdrawal through this mechanism.

DSM-5 Criteria — Severity Dimensions

The DSM-5 (2013) replaced the former dichotomy of "abuse" versus "dependence" with a single Substance Use Disorder diagnosis on a severity continuum, defined by 11 criteria across four domains:

• Impaired control (4 criteria): taking more than intended, unsuccessful attempts to cut down, significant time spent obtaining/using/recovering, craving.
• Social impairment (3 criteria): failure to fulfill major role obligations, continued use despite social problems, abandonment of activities.
• Risky use (2 criteria): use in physically hazardous situations, continued use despite physical or psychological problems known to be caused by use.
• Pharmacological (2 criteria): tolerance (need for markedly increased amounts), withdrawal.

Mild SUD = 2–3 criteria; moderate = 4–5; severe = 6+. Tolerance and withdrawal alone are insufficient for diagnosis — they may reflect normal physiological adaptation in patients using medications (e.g., opioids for pain). The change reflects understanding that addiction is about compulsive use despite harm, not merely physical dependence.

Effective treatments exist. Medication-assisted treatment (MAT) with buprenorphine-naloxone or methadone for opioid SUD reduces mortality by over 50% and is supported by every major medical organization — yet remains dramatically underutilized.